Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 11/20 | 0.43 |
| ▸ | CTSS | P25774 | 4/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5709570 | 1.00 | CA1 (0.50) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL23749683 | 1.00 | CA1 (0.50) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL9303984 | 0.86 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL9303991 | 0.86 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL1372203 | 0.83 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL17616112 | 0.83 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL3018246 | 0.83 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL27426180 | 0.83 | CYP2D6 (0.63) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL5198000 | 0.83 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL25270811 | 0.83 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115698003-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2017156181-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| US-6329502-B1 | VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS; TREATMENT OF AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | JAPAN ENERGY CORPORATION (JP) | 2001-12-11 | — | — | US | disclosed |
| US-6313094-B1 | COMPOSITION FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | JAPAN ENERGY CORPORATION (JP) | 2001-11-06 | — | — | US | disclosed |
| EP-0490667-B1 | HIV protease inhibitors | JAPAN ENERGY CORP (JP) | 1999-06-09 | — | — | EP | disclosed |
| US-5321036-A | Treatment of diabetes, obesity and gastrointestinal disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-06-14 | — | — | US | disclosed |
| EP-0490667-A2 | HIV protease inhibitors | JAPAN ENERGY CORPORATION (JP) | 1992-06-17 | — | — | EP | disclosed |